<?xml version="1.0" encoding="UTF-8"?><!-- generator="WordPress/2.9.2" -->
<rss version="0.92">
<channel>
	<title>Horizon Discovery Ltd.</title>
	<link>http://www.horizondiscovery.com</link>
	<description>Cancer Models for Targeted Drug Discovery</description>
	<lastBuildDate>Tue, 23 Feb 2010 06:23:18 +0000</lastBuildDate>
	<docs>http://backend.userland.com/rss092</docs>
	<language>en</language>
	
	<item>
		<title>Horizon Receive Eurostars Award; $500,000 Grant to Model Non-inherited SNPs That May Drive Human Cancer  »</title>
		<description><![CDATA[Horizon Discovery (Horizon) and the University of Torino, Department of Oncological Sciences, today announced that they have been awarded a three-year Eurostars grant under the EUREKA and EU Seventh Framework Programme for Research and Technological Development.
The grant application entitled “Interrogation of Somatic and Inherited Gene-variations for Human Therapy (INSIGHT)” was ranked first amongst all applications [...]]]></description>
		<link>http://www.horizondiscovery.com/news/horizon-and-university-of-torino-receive-eurostars-award-500000-grant-to-model-non-inherited-snps-that-may-drive-human-cancer-%c2%bb/</link>
			</item>
	<item>
		<title>Horizon Sign New Commercial Deals with Leading Pharma Companies  »</title>
		<description><![CDATA[Horizon Discovery (Horizon) today announced it has signed new commercial agreements with pharmaceutical companies Sanofi-Aventis and Centacor (a J&#38;J Ortho Company), relating to its X-MAN technology.
Horizon’s X-MAN (Mutant And Normal) cell-line technology provides the first genetically-defined and patient-relevant in vitro models of human cancer. These models are being used by a growing number of Pharma [...]]]></description>
		<link>http://www.horizondiscovery.com/news/horizon-sign-new-commercial-deals-with-leading-pharma-companies-%c2%bb/</link>
			</item>
	<item>
		<title>Horizon Discovery Completes Materials Transfer Agreement with Sunesis Pharmaceuticals  »</title>
		<description><![CDATA[Horizon Discovery (Horizon) today announced it has signed a material transfer agreement with Sunesis Pharmaceuticals, Inc., (Sunesis) relating to its X-MAN technology.
Horizon’s X-MAN (Mutant And Normal) cell-line technology provides the first genetically-defined and patient-relevant in vitro models of human cancer. These models are being used by a growing number of Pharma and Biotech companies to [...]]]></description>
		<link>http://www.horizondiscovery.com/news/horizon-discovery-completes-materials-transfer-agreement-with-sunesis-pharmaceuticals-%c2%bb/</link>
			</item>
	<item>
		<title>The Translational Genomics Research Institute becomes center of excellence for GENESIS and X-MAN technology »</title>
		<description><![CDATA[Horizon Discovery and the Translational Genomics Research Institute (TGen) today announced plans to develop human disease models for use in TGen’s cancer research.
A research-collaboration and sub-licensing agreement will allow TGen investigators to use Horizon’s GENESIS™ and X-MAN™ technologies to accelerate the search for new drug targets, biomarkers and anti-cancer agents, which could provide patients with [...]]]></description>
		<link>http://www.horizondiscovery.com/news/the-translational-genomics-research-institute-tgen-becomes-center-of-excellence-for-horizon-discovery%e2%80%99s-genesis-and-x-man-technology-%c2%bb/</link>
			</item>
	<item>
		<title>UK Translational Genomics Company Horizon Discovery Launches New Companion Diagnostics Venture »</title>
		<description><![CDATA[Horizon Discovery (Horizon) the translational genomics firm recently named the UK’s most innovative company at the inaugural ‘iawards’ has announced the formation of a new subsidiary venture, Horizon Dx Ltd (HDx). The company will support the development, approval and sale of companion diagnostic products initially in the field of cancer. 
At the center of the [...]]]></description>
		<link>http://www.horizondiscovery.com/news/uk-translational-genomics-company-horizon-discovery-launches-new-companion-diagnostics-venture-%c2%bb/</link>
			</item>
	<item>
		<title>Horizon Discovery Sign Multi-Year Technology Access Agreement with Genentech Incorporated  »</title>
		<description><![CDATA[December 2009 &#8211; Through an additional agreement, Horizon Discovery has provided open access to its 150+ strong X-MAN™ cell-line library to Genentech, Inc., a wholly-owned member of the Roche Group,  for a period of up to three years. Genentech will utilize the in-licensed cell-line panels in its oncology research programs. The relationship builds on [...]]]></description>
		<link>http://www.horizondiscovery.com/news/horizon-discovery-sign-multi-year-technology-access-agreement-with-genentech/</link>
			</item>
	<item>
		<title>Horizon Discovery and University of Washington Expand Gene-Targeting Licenses to Include Bioproduction &amp; Stem Cell Applications   »</title>
		<description><![CDATA[Horizon Discovery (Horizon) and University of Washington (UW) today announced they have entered into two additional exclusive licensing agreements in the area of human gene-targeting.
The new agreements give Horizon a world-wide exclusive right to commercialize inventions made by Professor David Russell, Professor of Medicine, Division of Hematology; Adjunct Professor of Biochemistry, University of Washington School [...]]]></description>
		<link>http://www.horizondiscovery.com/news/horizon-discovery-and-university-of-washington-expand-gene-targeting-licenses-to-include-bioproduction-stem-cell-applications/</link>
			</item>
	<item>
		<title>Horizon Discovery Signs Four-Year Collaboration with World-Leading Pharma to Develop X-MAN Cell-Lines  »</title>
		<description><![CDATA[Horizon Discovery (Horizon) today announced it has entered into a four-year strategic collaboration with Novartis. This is the second business agreement between the companies and sees the use of Horizon’s proprietary GENESISTM gene-engineering platform to develop a broad panel of custom generated genetically-defined human ‘X-MAN’ cancer models for deployment in Novartis’s drug discovery research programs.
X-MAN [...]]]></description>
		<link>http://www.horizondiscovery.com/news/horizon-discovery-signs-four-year-collaboration-with-world-leading-pharma-to-develop-x-man-cell-lines-%c2%bb/</link>
			</item>
	<item>
		<title>Horizon Discovery to Expand and Establish New UK Headquarters at IQ Cambridge  »</title>
		<description><![CDATA[Horizon Discovery (Horizon), the UK Personalized Medicine company recently announced as the Best Technology Start-Up and Best Technology Company at the inaugural UK government sponsored iawards, today announced that it is to expand its operations to include a purpose-fitted office and wet-lab facility at IQ Cambridge which will house up to 20 new staff.
The move [...]]]></description>
		<link>http://www.horizondiscovery.com/news/horizon-discovery-to-expand-and-establish-new-uk-headquarters-at-iq-cambridge-%c2%bb/</link>
			</item>
	<item>
		<title>Expand Your Horizons and Join the iawards Technology Start-Up and Company of the Year 2009   »</title>
		<description><![CDATA[Horizon is providing a road-map to drug developers, regulatory bodies, clinicians and healthcare providers to break the cycle of ‘irrational’ cancer drug development. By developing and marketing key in-vitro discovery and diagnostic tools Horizon’s mission is to enable both the faster development of improved ‘targeted’ anti-cancer drugs like Herceptin, Vectibix and Erbitux and the validation [...]]]></description>
		<link>http://www.horizondiscovery.com/news/expand-your-horizons-and-join-1-of-the-official-top-3-uk-technology-start-ups/</link>
			</item>
</channel>
</rss>
